Nipah Virus in India: Why Experts Say a Pandemic is Unlikely
Table of Contents
The World Health Organization maintains a low global risk assessment for the recent Nipah virus cases in India, citing key differences in transmission and lethality compared to COVID-19.
Two cases of Nipah virus (NiV) infection have been confirmed this month in West Bengal, India, prompting a response from national health authorities and a risk assessment from the World Health Organization (WHO). While the emergence of any novel virus understandably raises concerns, experts emphasize that the characteristics of Nipah virus – namely its difficult transmission, high fatality rate, and limited geographic distribution – significantly reduce the likelihood of a widespread pandemic akin to the COVID-19 crisis.
The confirmed cases involve two healthcare professionals, a man who is reportedly recovering and a woman in serious condition. As of Thursday, September 28th, there have been no reports of further transmission, according to Indian Ministry of Health officials. The WHO assessment echoes this, stating “there is no evidence of increased person-to-person transmission.” India, the WHO noted, has demonstrated its capacity to manage Nipah outbreaks, with public health measures being jointly implemented by national and state health teams.
The regional risk in West Bengal is classified as moderate due to the presence of natural reservoirs of the virus – fruit bats – in the area. However, the WHO considers the probability of spread to other Indian states or internationally to be low. This contrasts sharply with the rapid global dissemination of SARS-CoV-2, the virus that causes COVID-19.
The recent cases in India have inevitably drawn comparisons to the COVID-19 pandemic. Both Nipah and SARS-CoV-2 are classified as emerging viruses capable of causing severe illness, but crucial distinctions exist. These differences, experts say, make a global pandemic on the scale of COVID-19 unlikely, though not impossible.
The primary difference lies in how the viruses spread. “Nipah Virus infection requires more intimate and prolonged contact related to bodily fluids and fruits contaminated by the regional bat in places where there are cases, for example,” explains Fernando Dias e Sanches, a researcher at the Federal University of Rio de Janeiro (UFRJ) and Nipah virus scholar. This is a stark contrast to the ease with which the coronavirus spreads through airborne particles.
Another key factor limiting the spread of Nipah is its high lethality. “Patients die before they can transmit the disease,” highlights virologist Benedito Fonseca, professor at the Faculty of Medicine of Ribeirão Preto (FMRP/USP) and consultant at the Brazilian Society of Infectious Diseases (SBI). The Nipah virus initially presents symptoms similar to the flu, but can rapidly progress to severe encephalitis, causing neurological, vascular, and respiratory impairment.
This high mortality rate – estimated between 40% and 75% depending on early detection and quality of care – paradoxically hinders its ability to spread widely. Furthermore, the virus’s geographic distribution has been relatively restricted over the past two decades, largely concentrated in Southeast Asia where its natural reservoirs, Pteropus bats, reside. Historically, outbreaks have been limited to India and Bangladesh, occurring sporadically or in small clusters. The WHO reports that human-to-human transmission is rare, typically confined to healthcare settings or close family contacts, and there have been no reports of international spread linked to travel.
Fonseca further explains that the Nipah virus’s ability to adapt to humans appears limited. While the initial outbreak occurred after pigs were infected by bats and then transmitted the disease to humans, the coronavirus “did not require another animal reservoir to maintain high transmission of the disease.” The expectation, according to Fonseca, is that Nipah will not exhibit the same ease of adaptation. However, he cautions, “this is a new disease and we do not know, for sure, to how many people a patient infected with Nipah can transmit the virus.” Current expert opinion, however, suggests this risk remains low.
Prevention is Key in the Absence of Treatment
Currently, there is no licensed vaccine or specific treatment for Nipah virus infection, although several candidates are in development. Clinical management relies on early supportive treatment, including intensive care for severe respiratory or neurological complications, to maximize chances of survival.
Therefore, the WHO emphasizes the importance of infection prevention and control measures, particularly in healthcare facilities, and raising public awareness to reduce exposure risk. Key guidelines include:
- Using protective clothing and gloves when handling sick animals, during slaughter, or disposal.
- Reducing unprotected close contact with infected individuals and practicing regular hand hygiene.
- Implementing robust infection control measures in healthcare environments, including adequate ventilation, risk assessment, and appropriate use of personal protective equipment when treating suspected or confirmed cases.
The WHO continues to collaborate closely with Indian national and state health authorities to support risk assessment, surveillance, and outbreak response efforts. While the emergence of Nipah virus warrants vigilance, the current understanding of its characteristics suggests that a global pandemic remains unlikely.
